rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2016-478-481rsp-2279Research ArticleКЛИНИЧЕСКОЕ НАБЛЮДЕНИЕCLINICAL OBSERVATIONSРеакция со стороны кожных покровов и придатков кожи у больных ревматоидным артритом в период подкожного применения метотрексата: описание трех случаевThe reaction of the skin and its appendages in rheumatoid arthritis patients using subcutaneous methotrexate: A description of three casesМуравьевЮ. В.MuravyevYu. V.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

myrawyw@mail.ruГридневаГ. И.GridnevaG. I.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

Раденска-ЛоповокС. Г.Radenska-LopovokS. G.

115522 Москва, Каширское шоссе, 34А

34A, Kashirskoe Shosse, Moscow 115522

ХаритоноваН. И.KharitonovaN. I.

107078 Москва, Каланчевская улица, 31

31, Kalanchevskaya Street, Moscow 107078

ФГБНУ Научно- исследовательский институт ревматологии им. В.А. Насоновой, МоскваРоссияV.A. Nasonova Research Institute of Rheumatology, MoscowRussian FederationФГБУ «Федеральный медицинский центр» Росимущества, МоскваРоссияFederal Medical Center, Russian Federal Property Management Agency, MoscowRussian Federation201620102016544478481Copyright © Муравьев Ю.В., Гриднева Г.И., Раденска-Лоповок С.Г., Харитонова Н.И., 20162016Муравьев Ю.В., Гриднева Г.И., Раденска-Лоповок С.Г., Харитонова Н.И.Muravyev Y.V., Gridneva G.I., Radenska-Lopovok S.G., Kharitonova N.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2279

Сообщается о развитии неблагоприятных реакций со стороны кожных покровов и придатков кожи у больных ревматоидным артритом в период подкожного применения метотрексата, служащих проявлением его токсичности. Обсуждаются возможные механизмы их возникновения, хотя как клиническая картина, так и гистологические изменения неспецифичны. 

The paper reports the development of the adverse events of the skin and its appendages due to subcutaneous methotrexate, which serve as a manifestation of its toxicity in patients with rheumatoid arthritis. It discusses the possible mechanisms of their occurrence, although both clinical presentations and histological changes are not specific. 

метотрексатподкожное применениеревматоидный артритнеблагоприятные реакцииmethotrexatesubcutaneous userheumatoid arthritisadverse eventsReferencesSchmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009;146(5):489-503. doi: 10.1111/j.1365-2141.2009.07765.xSchmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009;146(5):489-503. doi: 10.1111/j.1365-2141.2009.07765.xFrei E, Blum RH, Pitman SW, et al. High-dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med. 1980;68(3):370-6. doi: 10.1016/0002- 9343(80)90105-9Frei E, Blum RH, Pitman SW, et al. High-dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med. 1980;68(3):370-6. doi: 10.1016/0002- 9343(80)90105-9Del Pozo J, Martinez W, Garcia-Silva J, et al. Cutaneous ulceration as a sign of methotrexate toxicity. Eur J Dermatol. 2001;11(5):450-2.Del Pozo J, Martinez W, Garcia-Silva J, et al. Cutaneous ulceration as a sign of methotrexate toxicity. Eur J Dermatol. 2001;11(5):450-2.Pearce HP, Wilson BB. Erosion of psoriatic plaques: an early sign of methotrexate toxicity. J Am Acad Dermatol. 1996;35 (5 Pt 2):835-8. doi: 10.1016/S0190-9622(96)90097-3Pearce HP, Wilson BB. Erosion of psoriatic plaques: an early sign of methotrexate toxicity. J Am Acad Dermatol. 1996;35 (5 Pt 2):835-8. doi: 10.1016/S0190-9622(96)90097-3Yelamos O, Catala A, Vilarrasa E, et al. Acute severe methotrexate toxicity in patients with psoriasis: a case series and discussion. Dermatology. 2014;229(4):306-9. doi: 10.1159/000366501Yelamos O, Catala A, Vilarrasa E, et al. Acute severe methotrexate toxicity in patients with psoriasis: a case series and discussion. Dermatology. 2014;229(4):306-9. doi: 10.1159/000366501Jindal N, Arora K, Jindal P, et al. Inflamed psoriatic plaques: drug toxicity or disease exacerbation? Ind J Pharmacol. 2013;45(4):410-1. doi: 10.4103/0253-7613.115001Jindal N, Arora K, Jindal P, et al. Inflamed psoriatic plaques: drug toxicity or disease exacerbation? Ind J Pharmacol. 2013;45(4):410-1. doi: 10.4103/0253-7613.115001Sanz-Sanchez T, Romero-Mate A, Tardхo JC, et al. Acantholytic dermatosis in psoriaticpatient with methotrexate toxicity. J Eur Acad Dermatol Venereol. 2008;22(10):1236-7. doi: 10.1111/j.1468- 3083.2007.02551.xSanz-Sanchez T, Romero-Mate A, Tardхo JC, et al. Acantholytic dermatosis in psoriaticpatient with methotrexate toxicity. J Eur Acad Dermatol Venereol. 2008;22(10):1236-7. doi: 10.1111/j.1468- 3083.2007.02551.xGaigl Z, Seitz CS, Brocker EB, Trautmann A. Methotrexateinduced toxic epidermal necrolysis-like skin toxicity. Eur J Dermatol. 2007;17(2):168-9.Gaigl Z, Seitz CS, Brocker EB, Trautmann A. Methotrexateinduced toxic epidermal necrolysis-like skin toxicity. Eur J Dermatol. 2007;17(2):168-9.Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645-8.Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol. 2004;31(4):645-8.Braun J, Kä stner P, Flaxenberg P, et al.; MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58(1):73-81. doi: 10.1002/art.23144Braun J, Kä stner P, Flaxenberg P, et al.; MC-MTX.6/RH Study Group. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum. 2008;58(1):73-81. doi: 10.1002/art.23144Каратеев ДЕ, Лучихина ЕЛ, Муравьев ЮВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013;51(2):117-25 [Karateev DE, Luchikhina EL, Muravyev YuV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(2):117-25 (In Russ.)]. doi: 10.14412/1995-4484-2013-637Каратеев ДЕ, Лучихина ЕЛ, Муравьев ЮВ и др. Первое российское стратегическое исследование фармакотерапии ревматоидного артрита (РЕМАРКА). Научно-практическая ревматология. 2013;51(2):117-25 [Karateev DE, Luchikhina EL, Muravyev YuV, et al. The first Russian strategic study of pharmacotherapy for rheumatoid arthritis (REMARCA). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2013;51(2):117-25 (In Russ.)]. doi: 10.14412/1995-4484-2013-637Delyon J, Ortonne N, Benayoun E, et al. Low-dose methotrexateinduced skin toxicity: Keratinocyte dystrophy as a histologic marker. J Am Acad Dermatol. 2015;73(3):484-90. doi: 10.1016/j.jaad.2015.06.015Delyon J, Ortonne N, Benayoun E, et al. Low-dose methotrexateinduced skin toxicity: Keratinocyte dystrophy as a histologic marker. J Am Acad Dermatol. 2015;73(3):484-90. doi: 10.1016/j.jaad.2015.06.015Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001;98:231-4. doi: 10.1182/blood.V98.1.231Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood. 2001;98:231-4. doi: 10.1182/blood.V98.1.231Toffoli G, Veronesi A, Boiocchi M, et al. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide,methotrexate and luorouracil (CMF). Ann Oncol. 2000;11:373-4. doi: 10.1023/A:1008337900349Toffoli G, Veronesi A, Boiocchi M, et al. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide,methotrexate and luorouracil (CMF). Ann Oncol. 2000;11:373-4. doi: 10.1023/A:1008337900349Choe JY, Lee H, Jung HY, et al. Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis. Rheumatol Int. 2012;32:1837-42. doi: 10.1007/s00296-011-1989-5Choe JY, Lee H, Jung HY, et al. Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis. Rheumatol Int. 2012;32:1837-42. doi: 10.1007/s00296-011-1989-5

The authors declare that there are no conflicts of interest present.